Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cancer drugs pricing

- PMLiVE

First NHS patient treated with Novartis’ SMA gene therapy Zolgensma

Novartis and NHS England reached a landmark deal for the gene therapy earlier this year

- PMLiVE

Novartis, Molecular Partners launch global study of novel COVID-19 drug

Initial positive phase 1 study results found that the drug was safe and well tolerated, with no significant adverse events reported

- PMLiVE

BeiGene, Novartis’ tislelizumab report promising topline results in nasopharyngeal cancer

In 2018, 46.9% of global cases of nasopharyngeal cancer occurred in China

- PMLiVE

Sandoz reveals antibiotic manufacturing expansion plans in Europe

Builds on company's previous commitments to drive the long-term future of integrated antibiotics manufacturing in Europe

- PMLiVE

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

Amgen will retain market exclusivity on blockbuster arthritis drug until 2029

- PMLiVE

Novartis announces delay in UK cholesterol drug study

The delay was caused by recruitment issues during the COVID-19 pandemic

Building Better Access to Pediatric Care Through Telehealth

Jeannie Chen, Head of Clinical Operations and People at Hazel Health, shares her insights on telemedicine and virtual care as means to improve healthcare access and equity among school-aged children....

Impetus Digital

Novartis day

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

New post hoc data comes from phase 3 ASCLEPIOS trials

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

- PMLiVE

FDA approves new self-injection administration for Xolair

Drug is approved for asthma and other allergic and inflammatory conditions

- PMLiVE

WHITE PAPER: Why do men die younger?

It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...

IGNIFI

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links